Arkolith/Insider Trading/TRIL/Form 4

Skvarka Jan

President and CEO, DirectorTrillium Therapeutics Inc. (TRIL) · full profile →Form 4 · filed May 13, 2021
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.2M
Net Open-Market Flow
-$1.2M
Transactions
8
5 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 12, 2021Sell(S)24K$9.24$220K0
May 12, 2021Option exercise(M)24K$0.31$7K24K
May 11, 2021Option exercise(M)88K$0.45$39K88K
May 11, 2021Sell(S)107K$9.20$982K0
May 11, 2021Option exercise(M)19K$0.31$6K107K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 12, 2021Option exercise(M)24K—$0197K
May 11, 2021Option exercise(M)88K—$01.2M
May 11, 2021Option exercise(M)19K—$0221K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001062993-21-004511) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML